Rate of isolation and trends of antimicrobial resistance of multidrug resistant pseudomonas aeruginosa from otorrhea in chronic suppurative otitis media

Clinical and Experimental Otorhinolaryngology

Volumn 5, Issue 1, 2012, Pages 17-22

  Lee, Sun Kyu ^a   Park, Dong Choon ^b   Kim, Myung Gu ^c   Boo, Sung Hyun ^c   Choi, Young Joon ^a   Byun, Jae Yong ^a   Park, Moon Suh ^a   Yeo, Seung Geun ^a  

^a Kyung Hee University Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Chronic suppurative otitis media; Multidrug resistant; Pseudomonas aeruginosa

Indexed keywords

EID: 84859139539     PISSN: 19768710     EISSN: 20050720     Source Type: Journal    
DOI: 10.3342/ceo.2012.5.1.17     Document Type: Article

References (22)

1. Bergogne-Berezin E. Pseudomonas and miscellaneous gram-negative bacilli. In: Cohen J, Powderly WG, editors. Infectious diseases. 2nd ed. Philadelphia, PA: Mosby; 2004. p. 2203-26.
2. Song W, Woo HJ, Kim JS, Lee KM. In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2003 Jan;21(1):8-12.
3. Park DC, Lee SK, Cha CI, Lee SO, Lee MS, Yeo SG. Antimicrobial resistance of Staphylococcus from otorrhea in chronic suppurative otitis media and comparison with results of all isolated Staphylococci. Eur J Clin Microbiol Infect Dis. 2008 Jul;27(7):571-7.
4. Wikler MA; Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: sixteenth informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
5. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002 Mar 1;34(5):634-40.
6. Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 5th ed. Edinburgh, UK: Churchill Livingstone; 2000. p. 2310-27.
7. Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis. 2002 Jul;43(3):239-43.
8. Walsh TR, Toleman MA, Hryniewicz W, Bennett PM, Jones RN. Evolution of an integron carrying blaVIM-2 in Eastern Europe: report from the SENTRY Antimicrobial Surveillance Program. J Antimicrob Chemother. 2003 Jul;52(1):116-9.
9. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999 Jun;43(6):1379-82.
10. Llano-Sotelo B, Azucena EF Jr, Kotra LP, Mobashery S, Chow CS. Aminoglycosides modified by resistance enzymes display diminished binding to the bacterial ribosomal aminoacyl-tRNA site. Chem Biol. 2002 Apr;9(4):455-63.
11. MacLeod DL, Nelson LE, Shawar RM, Lin BB, Lockwood LG, Dirk JE, et al. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J Infect Dis. 2000 Mar;181(3):1180-4.
12. Jo JT, Brinkman FS, Hancock RE. Aminoglycoside efflux in Pseudomonas aeruginosa: involvement of novel outer membrane proteins. Antimicrob Agents Chemother. 2003 Mar;47(3):1101-11.
13. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis. 2007 Jul 1;45(1):88-94.
14. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001 Mar-Apr;7(2):337-41.
15. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2000 Dec;44(12):3322-7.
16. Vahaboglu H, Hall LM, Mulazimoglu L, Dodanli S, Yildirim I, Livermore DM. Resistance to extended-spectrum cephalosporins, caused by PER-1 beta-lactamase, in Salmonella typhimurium from Istanbul, Turkey. J Med Microbiol. 1995 Oct;43(4):294-9.
17. Mugnier P, Dubrous P, Casin I, Arlet G, Collatz E. A TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1996 Nov;40(11):2488-93.
18. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991 Jan;35(1):147-51.
19. Lee K, Kim YA, Park YJ, Lee HS, Kim MY, Kim EC, et al. Increasing prevalence of vancomycin-resistant enterococci, and cefoxitin-, imipenem- and fluoroquinolone-resistant gram-negative bacilli: a KONSAR study in 2002. Yonsei Med J. 2004 Aug 31;45(4):598-608.
20. Lee H, Yong D, Lee K, Hong SG, Kim EC, Jeong SH, et al. Antimicrobial resistance of clinically important bacteria isolated from 12 hospitals in Korea in 2004. Korean J Clin Microbiol. 2005 Apr;8(1):66-73.
21. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005 May 1;40(9):1333-41.
22. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis. 2005 Apr 8;5:24.